-+ 0.00%
-+ 0.00%
-+ 0.00%

BMO Capital Maintains Outperform on AbbVie, Raises Price Target to $300

Benzinga·07/13/2026 12:56:20
Listen to the news
BMO Capital analyst Evan David Seigerman maintains AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $258 to $300.